12th Annual Endoscopy Course

Friday, October 17, 2025, 8:00 AM - Saturday, October 18, 2025, 5:00 PM, Newport Marriott Hotel & Spa, Newport, RI

The field of endoscopy has rapidly evolved with the introduction of innovative diagnostic techniques and novel therapies. The endoscopist frequently encounters difficult issues and controversies in patient management. “The Endoscopy Course” is designed to take a case-based approach to understand the current role of endoscopy in the care of patients with a variety of gastrointestinal diseases. Numerous challenging topics will be explored, including the basics of endoscopy, innovations in upper and lower GI disorders, gastrointestinal bleeding, and pancreas and biliary tract disorders. As always, the highlight of this unique educational symposium are the debates between Harvard and Yale faculty on areas of endoscopic controversy. This program is designed for practicing gastroenterologists, gastroenterology fellows, nurses, advanced practice providers interested in the care of patients with gastrointestinal diseases and the latest information on state of the art of endoscopic diagnosis and treatment of these illnesses. LEARNING OBJECTIVES • Review new considerations with regard to endoscopy and gastrointestinal bleeding including management of antithrombotic agents and sedation • Implement methods for improving colonoscopy quality, removal of difficult polyps and endoscopic mucosal resection • Practice new developments in therapeutic EUS including biliary and pancreatic drainage and management of small bowel obstruction • Discuss developments in Bariatric Endoscopy

1. Review new considerations with regard to endoscopy and gastrointestinal bleeding including management of antithrombotic agents and sedation
2. Implement methods for improving colonoscopy quality, removal of difficult polyps and endoscopic mucosal resection
3. Practice new developments in therapeutic EUS including biliary and pancreatic drainage and management of small bowel obstruction
4. Discuss developments in new endoscopic sedation guidelines with respect to GLP 1 agonist use

Registration fee* includes continental breakfasts, refreshment breaks, and lunch:

• Physicians — $350
• Advanced Practice Providers — $200
• Endoscopy Nurses — $200
• Residents/Fellows† — $150  
• Brown University, Harvard and Yale Fellows and Residents — Complimentary, registration required 
• Brown University, Harvard,Yale and VA Nurses & Techs — Complimentary, registration required 
  
  

*All cancellations must be received in writing (or via email) at least 20 days prior to the start of the conference to receive a refund.  Any requests for refunds received after this date, or by telephone, will not be honored.
†A letter of verification from department head must accompany registration. Letter should be sent separately to Yale CME at the address below. You may also e-mail a pdf copy of your verification letter to [email protected].

If paying via check, include conference name in the memo, make check payable to Yale University and send to:
Yale University
Center for Continuing Medical Education
c/o Farrah Nettleton
367 Cedar Street – ESH Building A – 2nd floor
New Haven, CT 06510-3240

If you have any questions, please contact the Center for Continuing Medical Education at [email protected].

Accreditation Statement
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Designation Statement
The Yale School of Medicine approves this educational activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC POINTS ~ Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.75 Medical Knowledge Only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Policy
It is the policy of Yale School of Medicine, Continuing Medical Education (CME), to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All individuals involved in the development and presentation of Accredited Continuing Education activities are required to disclose all financial relationship(s) with ineligible companies (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) that has occurred within the past 24 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. This information is disclosed to all activity participants prior to the commencement of the educational activity.

Mitigation of Financial Relationships Statement
Yale CME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Financial Statement
The Yale School of Medicine, Department of Internal Medicine, Section of Digestive Diseases is grateful to its supporters.  They are acknowledged in all conference materials.

AMA PRA Category 1 Credits™ (12.75 hours), Non-Physician Attendance (12.75 hours)

Mitigation of Relevant Financial Relationships

Yale Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

W9 Form Register to Reserve Exhibit Table